XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Acquisitions, Research Collaborations and License Agreements - Acquisitions (Details) - USD ($)
$ in Millions
1 Months Ended
Jan. 16, 2020
Apr. 01, 2019
Jul. 31, 2020
Jun. 30, 2020
May 31, 2020
Apr. 30, 2019
Dec. 31, 2019
Jun. 30, 2019
Dec. 31, 2018
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Contingent consideration       $ 798.0     $ 767.0 $ 753.0 $ 788.0
Goodwill       20,067.0     $ 19,425.0    
Themis                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Payment to acquire business       366.0          
Contingent consideration, maximum       740.0          
Contingent consideration       97.0          
IPR&D       136.0          
Cash and cash equivalents       62.0          
Goodwill       215.0          
Deferred tax assets       72.0          
Other assets and liabilities, net       (22.0)          
ArQule                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Payment to acquire business $ 2,700.0                
Share-based compensation payments attributable to precombination service 138.0                
Transaction costs 95.0                
Cash and cash equivalents 145.0                
Goodwill 414.0                
Other assets and liabilities, net $ 35.0                
Antelliq                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Payment to acquire business   $ 2,300.0              
Transaction costs   47.0              
Cash and cash equivalents   31.0              
Goodwill   1,376.0              
Debt assumed and paid   1,300.0              
Other assets and liabilities, net   $ (82.0)              
Immune Design                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Payment to acquire business           $ 301.0      
IPR&D           156.0      
Cash and cash equivalents           83.0      
Other net assets           42.0      
Goodwill           $ 20.0      
Development Milestones | Themis                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Contingent consideration, maximum       80.0          
Sales-Based Milestones | Themis                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Contingent consideration, maximum       400.0          
Regulatory Milestones | Themis                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Contingent consideration, maximum       $ 260.0          
IAVI                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Upfront and milestone payments         $ 6.5        
Contingent milestone payments collaborative arrangement         $ 100.0        
Technology Rights | Subsequent Event | Virbac                  
Acquisitions Research Collaborations And License Agreements Transactions [Line Items]                  
Acquired rights     $ 400.0